TABLE 2.

Hepatocellular carcinoma treatment modalities used by the included studies

Study	Year	TACE n	TACE modality	TACE treatment	TARE n	TARE modality	TARE treatment
Akinwande 24	2016	28	DEB‐TACE	Lobar and selective	20	TheraSphere	Lobar
Akinwande 21	2015	291	DEB‐TACE	Lobar and selective	67	TheraSphere	Lobar
Auer 30	2021	18	DSM‐TACE	Lobar	18	SIR‐Sphere	Lobar
Biederman 22	2018	877	DEB‐TACE	Selective	534	TheraSphere	Lobar
Carr 29	2010	691	cTACE	Lobar and selective	99	TheraSphere	Lobar
El Fouly 20	2014	42	cTACE	Selective	44	TheraSphere	Lobar
Kooby 19	2010	44	cTACE	Selective	27	SIR‐Sphere	Lobar
Lance 18	2011	35	cTACE and DEB‐TACE	Selective	38	TheraSphere and SIR‐Sphere	Lobar and Selective
Massani 16	2017	82	cTACE and DEB‐TACE	Lobar and Selective	39	SIR‐Sphere	Lobar
McDevitt 27	2017	24	DEB‐TACE	NS	26	TheraSphere	NS
Moreno‐Luna 14	2012	55	cTACE	Lobar and Selective	61	TheraSphere	Lobar
Padia 26	2017	77	cTACE and DEB‐TACE	Selective	101	TheraSphere	Selective
Pitton 25	2014	12	DEB‐TACE	Selective	12	SIR‐Sphere	Lobar
Salem 23	2011	122	cTACE	NS	123	TheraSphere	NS
Salem 10	2016	21	cTACE	NS	24	TheraSphere	NS
She 28	2014	16	cTACE	Lobar and Selective	16	SIR‐Sphere	Selective
Soydal 15	2016	40	cTACE	Selective	40	SIR‐Sphere	Selective

Abbreviations: cTACE, conventional transarterial chemoembolization; DEB, Drug eluting bead; DSM, degradable starch microsphere; NS, not specified; TACE, Transarterial chemoembolization; TARE, transarterial radioembolization.